SCHEMBL3000739

SCHEMBL3000739

Nc1cc2ccccc2c(=O)o1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MITF O75030 1/20 0.59
PTGES O14684 2/20 0.56
ELANE P08246 1/20 0.48
ALOX5 P09917 2/20 0.47
ALDH1A1 P00352 5/20 0.46
SMN1; SMN2 Q16637 3/20 0.46
HPGD P15428 3/20 0.46
KDM4E B2RXH2 3/20 0.46
MAPT P10636 2/20 0.46
TDP1 Q9NUW8 2/20 0.46
L3MBTL1 Q9Y468 2/20 0.46
CASP3 P42574 1/20 0.46
SENP7 Q9BQF6 1/20 0.46
TYMP P19971 1/20 0.46
NPC1 O15118 1/20 0.46
MAPK1 P28482 1/20 0.46
RAB9A P51151 1/20 0.46
KMT2A Q03164 1/20 0.46
POLB P06746 1/20 0.46
HTT P42858 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19583424 0.78 PTGES (0.78) MITFPTGESALOX5ALDH1A1SMN1; SMN2
SCHEMBL295233 0.75 PTGES (0.56) MITFPTGESELANEALOX5ALDH1A1
SCHEMBL28549436 0.75 PTGES (0.56) MITFPTGESALOX5ALDH1A1SMN1; SMN2
SCHEMBL295232 0.75 PTGES (0.56) MITFPTGESELANEALOX5ALDH1A1
SCHEMBL1649762 0.75 PTGES (0.56) MITFPTGESALOX5ALDH1A1SMN1; SMN2
SCHEMBL31661103 0.75 PTGES (0.56) MITFPTGESALOX5ALDH1A1SMN1; SMN2
SCHEMBL6449120 0.75 PTGES (0.56) MITFPTGESELANEALOX5ALDH1A1
SCHEMBL31604207 0.75 PTGES (0.56) MITFPTGESELANEALOX5ALDH1A1
SCHEMBL21058262 0.75 PTGES (0.56) MITFPTGESALOX5ALDH1A1SMN1; SMN2
SCHEMBL12958021 0.75 ELANE (0.50) ELANEALDH1A1HPGDKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120225873-A1 COMPOUNDS FOR ALZHEIMER'S DISEASE MYREXIS, INC. (US) 2012-09-06 US claimed
CN-119613320-A Synthesis method of compound 3-iodo-1H-indole-2-carboxylic acid 上海毕臣生化科技有限公司 2025-03-14 CN disclosed
EP-2970118-B1 COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS MANFREDI JOHN (US) 2018-09-12 EP disclosed
EP-2813498-B1 Compounds for Alzheimer's disease MANFREDI JOHN (US) 2016-04-20 EP disclosed
CN-103221397-B Novel compositions and methods for controlling nematode pests MONSANTO TECHNOLOGY LLC (US) 2016-04-13 CN disclosed
EP-2970118-A1 COMPOUNDS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS Manfredi, John (US) 2016-01-20 EP disclosed
US-9216966-B2 Compounds for Alzheimer's disease Manfredi, John (US) 2015-12-22 US disclosed
CN-104768931-A Compounds and therapeutic uses thereof ALZHEIMER S INST OF AMERICA INC 2015-07-08 CN disclosed
CN-103370316-B 3-aryl-6-aryl- [1,2,4] triazolo [4,3-a ] pyridines as cell proliferation inhibitors and uses thereof IMPACT THERAPEUTICS INC 2015-06-24 CN disclosed
US-9034871-B2 Compounds for Alzheimer's disease Manfredi, John (US) 2015-05-19 US disclosed
CN-1176941-C Caspase inhibitors and the use thereof ά 2004-11-24 CN disclosed
CN-1516700-A Substituted 4H-chromenes and analogs as activators ofgasp ases and inducers of apoptosis and use thereof ά 2004-07-28 CN disclosed
CN-1382119-A Substituted alpha-hydroxy acid caspase inhibitors and uses thereof CYTOVIA INC (US) 2002-11-27 CN disclosed
CN-1379785-A Caspase inhibitors for the treatment and prevention of chemotherapy and radiotherapy induced cell death CYTOVIA INC (US) 2002-11-13 CN disclosed
CN-1360591-A 3 alpha-hydroxy-3 beta-methoxymethyl-21-heterocyclic substituted steroids having anesthetic activity PIDU PHARMACEUTICAL INC (US) 2002-07-24 CN disclosed
CN-1349496-A Caspase inhibitors and uses thereof CYTOVIA INC (US) 2002-05-15 CN disclosed
CN-1346344-A Substituted 2-aminobenzamide caspase ihibitors and the use thereof CYTOVIA INC (US) 2002-04-24 CN disclosed
US-5324648-A Anticoagulants; antitumor agents GEORGIA TECH RESEARCH CORPORATION (US) 1994-06-28 US disclosed
US-4954519-A Isocoumarins with basic substituents as serine proteases inhibitors, anticoagulants and anti-inflammatory agents GEORGIA TECH RESEARCH CORPORATION (US) 1990-09-04 US disclosed
US-4845242-A ANTITUMOR GEORGIA TECH RESEARCH CORPORATION (US) 1989-07-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120225873-A1 COMPOUNDS FOR ALZHEIMER'S DISEASE PSEN2, CHAT, PSEN1 MITF 4590/4885PTGES 3226/4885ELANE 4785/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.